对低氧反应的高尔基向原药与人环素组合,改善抗瘤和抗转移效率
Chenqi Guo1,2, Mengying Wu2, Zhaofei Guo2
1Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
ACS nano
|December 13, 2023
概括
这项研究引入了一种新型前药物,该前药物针对戈尔吉装置治疗癌症转移. 这种针对戈尔吉的策略显示出开发新的抗转移疗法的前景.
科学领域:
- 生物医学工程 生物医学工程
- 癌症研究 癌症研究
- 药物运输 药物运输 药物运输
背景情况:
- 瘤转移是一种复杂的过程,涉及癌细胞中的戈尔吉器官功能障碍.
- 目前的戈尔吉向策略主要集中在诊断探针上,治疗应用有限.
- 戈尔吉综合体是对抗癌症转移的有希望的治疗标.
研究的目的:
- 开发一种新型前药物 (INR),以向并破坏用于癌症治疗的戈尔吉装置.
- 创建一个低氧反应药物输送系统,以提高瘤微环境中的治疗效果.
- 评估开发的纳米粒子配方 (PNP) 的抗转移潜力.
主要方法:
- 一种前药物 (INR) 的设计,包括用于戈尔吉向的印米他辛 (IMC) 和用于戈尔吉乱的视网酸 (RA),通过对缺氧反应的部分联系在一起.
- 使用乳液溶剂蒸发将INR制成无载体纳米粒子 (PNP),并进行PEGylation以获得稳定性.
- 在体外和体内对药物释放,戈尔吉干扰,抗转移活性和对初级瘤和转移的治疗疗效的评估.
主要成果:
- 在瘤细胞中,INR有效地释放了原型药物 (IMC和RA),缺氧增强了这种释放.
- 印米他辛 (IMC) 增强了视网膜酸 (RA) 的戈尔吉破坏作用,并抑制了前瘤的COX-2/PGE2信号传递.
- 基化纳米颗粒配方 (PNP) 显示出对4T1原发性瘤及其肺和肝转移的显著疗效.
结论:
- 成功开发了一种针对戈尔吉器官的小分子治疗前药物.
- 在纳米粒子输送系统中集成的Golgi向前药物策略,为治疗癌症转移提供了一个有前途的方法.
- 这项工作扩大了戈尔吉向策略在疾病治疗中的应用,并且可以适应各种药物输送系统和模型.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187